Publications Durham NC | HIV Publications & Articles

Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models

Tian M, McGovern K, Cheng HL, Waddicor P, Rieble L, Dao M, Chen Y, Kimble MT, Cantor E, Manfredonia N, Judson R, Chapdelaine-Williams A, Cain DW, Haynes BF, Alt FW. . Proc Natl Acad Sci U S A. 2020 Mar 24. pii: 201921996. doi: 10.1073/pnas.1921996117. [Epub ahead of print] PubMed PMID: 32209668.

Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants

Martinez DR, Tu JJ, Kumar A, Mangold JF, Mangan RJ, Goswami R, Giorgi EE, Chen J, Mengual M, Douglas AO, Heimsath H, Saunders KO, Nicely NI, Eudailey J, Hernandez G, Morgan-Asiedu PK, Wiehe K, Haynes BF, Moody MA, LaBranche C, Montefiori DC, Gao F, Permar SR. . mBio. 2020 Mar 10;11(2). pii: e00176-20. doi: 10.1128/mBio.00176-20. PubMed PMID: 32156815; PubMed Central PMCID: PMC7064758.

Subordinate Effect of -21M HLA-B Dimorphism on NK Cell Repertoire Diversity and Function in HIV-1 Infected Individuals of African Origin

Cubero EM, Ogbe A, Pedroza-Pacheco I, Cohen MS, Haynes BF, Borrow P, Peppa D. Front Immunol. 2020 Feb 18;11:156. doi: 10.3389/fimmu.2020.00156. eCollection 2020. PubMed PMID: 32132995; PubMed Central PMCID: PMC7041644.

Assessing the virulence of Cryptococcus neoformans causing meningitis in HIV infected and uninfected patients in Vietnam

Thanh LT, Toffaletti DL, Tenor JL, Giamberardino C, Sempowski GD, Asfaw Y, Phan HT, Van Duong A, Trinh NM, Thwaites GE, Ashton PM, Chau NVV, Baker SG, Perfect JR, Day JN. Med Mycol. 2020 Mar 20. pii: myaa013. doi: 10.1093/mmy/myaa013. [Epub ahead of print] PubMed PMID: 32196550.

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

Laher F, Moodie Z, Cohen KW, Grunenberg N, Bekker LG, Allen M, Frahm N, Yates NL, Morris L, Malahleha M, Mngadi K, Daniels B, Innes C, Saunders K, Grant S, Yu C, Gilbert PB, Phogat S, DiazGranados CA, Koutsoukos M, Van Der Meeren O, Bentley C, Mkhize NN, Pensiero MN, Mehra VL, Kublin JG, Corey L, Montefiori DC, Gray GE, McElrath MJ, Tomaras GD. PLoS Med. 2020 Feb 24;17(2):e1003038. doi: 10.1371/journal.pmed.1003038. eCollection 2020 Feb. PubMed PMID: 32092060; PubMedCentral PMCID: PMC7039414.

Variability in the Management of Adults with Pulmonary Nontuberculous Mycobacterial Disease

Abate G, Stapleton JT, Rouphael N, Creech B, Stout JE, El Sahly HM, Jackson L, Leyva FJ, Tomashek KM, Tibbals M, Watson N, Miller A, Charbek E, Siegner J, Sokol-Anderson M, Nayak R, Dahlberg G, Winokur P, Alaaeddine G, Beydoun N, Sokolow K, Kown NP, Phillips S, Baker AW, Turner N, Walter E, Guy E, Frey S. Clin Infect Dis. 2020 Mar 21. pii: ciaa252. doi: 10.1093/cid/ciaa252. [Epub ahead of print] PubMed PMID: 32198521.

Maternal gatekeepers: How maternal antibody Fc characteristics influence passive transfer and infant protection

Langel SN, Otero CE, Martinez DR, Permar SR. Maternal gatekeepers: How maternal antibody Fc characteristics influence passive transfer and infant protection. PLoS Pathog. 2020 Mar 26;16(3):e1008303. doi: 10.1371/journal.ppat.1008303. eCollection 2020 Mar. PubMed PMID: 32214394.

Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development

Roark HK, Jenks JA, Permar SR, Schleiss MR.J Infect Dis. 2020 Mar 5;221(Supplement_1):S60-S73. doi: 10.1093/infdis/jiz484. PubMed PMID: 32134481; PubMed Central PMCID: PMC7057791.

Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease

Nelson CS, Baraniak I, Lilleri D, Reeves MB, Griffiths PD, Permar SR.. J Infect Dis. 2020 Mar 5;221(Supplement_1):S45-S59. doi:10.1093/infdis/jiz428.

Safety and Immune Responses After a 12-month Booster in Healthy HIV-uninfected Adults in HVTN 100 in South Africa: A Randomized Double-Blind Placebo-Controlled Trial of ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 Vaccines

Laher F, Moodie Z, Cohen KW, Grunenberg N, Bekker LG, Allen M, Frahm N, Yates NL, Morris L, Malahleha M, Mngadi K, Daniels B, Innes C, Saunders K, Grant S, Yu C, Gilbert PB, Phogat S, DiazGranados CA, Koutsoukos M, Van Der Meeren O, Bentley C, Mkhize NN, Pensiero MN, Mehra VL, Kublin JG, Corey L, Montefiori DC, Gray GE, McElrath MJ, Tomaras GD. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020 Feb 24;17(2):e1003038. doi: 10.1371/journal.pmed.1003038. PMID: 32092060.

Publications